Endothelin receptor A antagonism reduces the extent of diffuse axonal injury in a rodent model of traumatic brain injury

Neurol Res. 2011 Mar;33(2):192-6. doi: 10.1179/016164111X12881719352453.

Abstract

Objectives: While endothelin-1 and its receptors have traditionally been associated with mediating vasoreactivity, we have recently shown that the vast majority of endothelin receptor A expression following traumatic brain injury is localized within the neuron. While it has been suggested that endothelin receptor A plays a role in influencing neuronal integrity, the significance of neuronally expressed endothelin receptor A remains unclear. One report suggests that endothelin-1 signaling mediates diffuse axonal injury. Therefore, this work sought to determine whether treatment with BQ-123, a selective endothelin receptor A antagonist, diminishes the extent of diffuse axonal injury following trauma.

Methods: A total of 12 male Sprague-Dawley rats (350-400 g) were used in this study. Two groups (n = 6 per group) were generated as follows: sham operation and traumatic brain injury+1·0 mg/kg BQ-123 delivered intravenously 30 minutes prior to the injury. Trauma was induced using a weight acceleration impact device. Animals were terminated 24 or 48 hours after trauma, and a series of six coronal sections through the entire anterior-posterior extent of the corpus callosum were selected from each brain for quantification of diffuse axonal injury by beta-amyloid precursor protein immunostaining.

Results: Our data indicated that animals treated with BQ-123 30 minutes prior to trauma showed a significant reduction in diffuse axonal injury in corpus callosum at both 24 and 48 hours post-injury.

Conclusion: The results show that endothelin receptor A antagonism reduced the extent of diffuse axonal injury, demonstrating a potential influence of the endothelin system on the intra-axonal cascade of molecular events underlying diffuse axonal injury.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antihypertensive Agents / administration & dosage
  • Axons / drug effects
  • Axons / pathology*
  • Axons / physiology*
  • Brain Injuries / drug therapy*
  • Brain Injuries / metabolism*
  • Brain Injuries / pathology
  • Diffuse Axonal Injury / drug therapy*
  • Diffuse Axonal Injury / metabolism*
  • Diffuse Axonal Injury / pathology
  • Disease Models, Animal
  • Endothelin A Receptor Antagonists*
  • Endothelin-1 / physiology
  • Injections, Intravenous
  • Male
  • Neuroprotective Agents / pharmacology
  • Peptides, Cyclic / administration & dosage
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Endothelin A / physiology*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Endothelin A Receptor Antagonists
  • Endothelin-1
  • Neuroprotective Agents
  • Peptides, Cyclic
  • Receptor, Endothelin A
  • cyclo(Trp-Asp-Pro-Val-Leu)